Anti-APRIL Antibody Holds >90% APRIL Suppression at 12 Weeks, ~70% Gd-IgA1 Cut
CLYM has more than doubled off its 52-week low of $1.635 on light trading volume (0.4× avg).
Summary
Climb Bio and Mabworks presented expanded Phase 1 healthy-volunteer data at ASN Kidney Week 2026 for CLYM116/MIL116, their anti-APRIL antibody for IgA nephropathy. A single subcutaneous dose of 480 mg or higher held free APRIL suppression above 90% through the full 12-week interval, and the 800 mg dose cut Gd-IgA1 by roughly 70% and IgA by about 60% at 12 weeks. The estimated ~33-day half-life and linear exposure with no target-mediated drug disposition support a once-every-12-weeks regimen, which is the dosing being tested in the enrolling NAVIGATE-2 Phase 2 trial. Safety looked clean: no dose-limiting toxicities, no treatment-related serious adverse events, and no hypogammaglobulinemia across doses from 25 mg to 1280 mg. This builds on the positive Phase 1 readout disclosed September 3rd and the 8-K that followed, adding durability and biomarker depth that management frames as a best-in-class profile against sibeprenlimab. NAVIGATE-2 patient data is expected in the first half of 2027, with a global Phase 3 targeted for 2027 pending regulatory feedback.
At the time of this announcement, CLYM was trading at $10.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $585.3M. The 52-week trading range was $1.64 to $18.33. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.